Form 4: Disc Medicine CLO Sells Shares After Option Exercise

Disc Medicine's Chief Legal Officer, Rahul Khara, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Rahul Khara, Chief Legal Officer of Disc Medicine, Inc., engaged in transactions on January 2, 2026.
• Exercised options to acquire 6,500 shares of common stock at an exercise price of $13.50 per share.
• Sold a total of 6,500 shares of common stock in three separate transactions.
• The sales occurred at weighted average prices of $77.6712 (350 shares), $78.6239 (4,993 shares), and $79.272 (1,157 shares).
• All reported transactions were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Khara beneficially owns 37,793 shares of common stock directly.
• He also holds 22,270 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The transactions represent a planned liquidity event for a company officer, executed under a 10b5-1 plan, which is a routine occurrence. The high sale price relative to the exercise price is positive for the officer's personal finances.

Positives

• The officer realized a significant personal gain by selling shares at prices ranging from $77.09 to $79.49, substantially higher than the option exercise price of $13.50.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled sales rather than discretionary market timing, which can mitigate negative investor perception.

Negatives

• An officer selling a significant number of shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is a common liquidity event for executives.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May view officer sales with caution, but the pre-arranged 10b5-1 plan mitigates the perception of opportunistic selling.
• Officer (Rahul Khara): Realized significant personal financial gain from the exercise and sale of shares.

Key Dates

Recommendation

This Form 4 reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 trading plan. Such planned sales by an officer, while reducing their direct holdings, do not typically signal a change in company fundamentals or warrant a change in investment recommendation. The significant profit realized by the officer from the option exercise is a personal financial event and not indicative of the company's future performance.

Keywords

Disc Medicine, IRON, Rahul Khara, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Legal Officer